William Blair analyst Matt Phipps in a note to investors wrote that despite the patient deaths, the totality of the data still leans in favor of Kezar Life Sciences’ investigational immunoproteasome inhibitor zetomipzomib.
Kezar Reports Four Patient Deaths in Mid-Stage Lupus Nephritis Study, Pauses Enrollment Read More »
Faced with potential monetary fines, Johnson & Johnson said Monday it is abandoning a proposed 340B rebate plan for hospitals involving two of its blockbuster drugs, Stelara and Xarelto.
J&J Reverses Course on 340B Rebate Plans Following HRSA Warning Read More »
District Judge Jesse Furman ruled that the plaintiff, UMB Bank, does not have standing to bring the case against Bristol Myers Squibb because it is not a properly appointed trustee for shareholders’ contingent value rights.
Federal Judge Dismisses $6.4B Lawsuit Against BMS Over Celgene Acquisition Read More »
As it shifts focus to a death receptor 3 (DR3) antagonist antibody, Shattuck Labs is cutting a significant number of employees before the end of the year.
From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite the journey to market. Former Karuna and Lilly executives discuss the “accidental” and “serendipitous” discovery.
The Making of BMS’ Cobenfy: From Alzheimer’s to Schizophrenia Read More »
A week after it released positive early-stage data, Metsera has partnered with Amneal Pharmaceuticals in an effort to secure the development and supply of its investigational weight loss therapy MET-097.
Obesity Startup Metsera Inks Manufacturing Pact With Amneal on Heels of Phase I Readout Read More »
Covering topics from digital health to financial management, these are some of the notable events and dates for executives at hospital systems, payers and technology firms to watch.
The lineup kicks off with the J.P. Morgan Healthcare Conference, followed by the American Academy of Orthopedic Surgeons meeting and DeviceTalks Boston.
Venture Capital firms Atlas Venture, Bain Capital Life Sciences and RTW Investments have led a $400 million series A for Kailera Therapeutics, the latest obesity biotech to hit the scene.
Kailera Launches With $400M to Advance China-Developed Obesity Assets Read More »
En el mundo actual, los casinos en línea se han convertido en una de las formas de entretenimiento más populares. La facilidad de acceso y la amplia oferta de juegos han hecho que millones de personas disfruten de estas plataformas desde la comodidad de sus hogares. Sin embar …
La seguridad en los casinos en línea: ¿Qué tan protegidos están los jugadores? Read More »
